medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2020, Number S1

<< Back Next >>

Ginecol Obstet Mex 2020; 88 (S1)

Complications caused by combined oral contraceptives. Thromboembolic events

Gómez-Tabares G

Language: Spanish
References: 35
Page: 140-155
PDF size: 270.89 Kb.


ABSTRACT

Despite the low incidence of venous thrombosis in women of reproductive age, its impact on users of oral contraceptives is wide. The consumption of oral contraceptives is estimated at 100 million users worldwide. The evaluation of the different combinations of contraceptives has an important role at the time of prescribing them. The aim of this study was to review the complications caused by combined oral contraceptives. A systematic review of the literature available in PubMed, EMBASE and Scopus databases was done, in which the terms “combined oral contraceptives”, “optimal doses of oral contraceptives”, “complications associated with oral contraceptives”, “venous thromboembolism” were searched. Inclusion criteria: articles of cases or series containing the sections of complications related to combined oral contraceptives and reporting at least 75% of the established clinical data. All current combined oral contraceptives confer similar efficacy to prevent pregnancy. In addition to their contraceptive effects, formulations with cyproterone acetate or drospirenone are prescribed for the treatment of acne vulgaris, seborrhea and mild hirsutism. Knowledge of the risks and complications of combined oral contraceptives is decisive. It is a priority to look for the safest option in each patient, in order to avoid the risk of venous thrombosis.


REFERENCES

  1. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998;877:1-89.

  2. Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol 1998;179:S62-S67.

  3. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30. https://doi.org/10.1161/01. CIR.0000078464.82671.78

  4. Dahlman-Wright K, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773- 81. https://doi.org/10.1124/pr.58.4.8

  5. Dickson RB, et al. 17 Alpha-ethinyl estradiol is more potent than estradiol in receptor interactions with isolated hepatic parenchymal cells. Endocrinology 1981;108:1511-8. https://doi.org/10.1210/endo-108-4-1511

  6. Fruzzetti F, et al. Review of clinical experience with estradiol in combined oral contraceptives. Contraception 2010;81:8- 5. https://doi.org/10.1016/j.contraception.2009.08.010.

  7. Mueck AO, et al. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531-9. https://doi. org/10.1016/j.steroids.2011.02.002.

  8. Mueck AO, et al. Why use of dienogest for the first contraceptive pill with estradiol? Gynecol Endocrinol 2009;26:109- 13. https://doi.org/10.3109/09513590903184167.

  9. Stanczyk FZ, et al. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013;87:706-727. https://doi.org/10.1016/j.contraception. 2012.12.011.

  10. Kemmeren JM, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004;103:927-33. https://doi.org/10.1182/ blood-2003-04-1285

  11. Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-85.

  12. Junge W, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011;31:573-84. https://doi.org/10.2165/11590220- 000000000-00000.

  13. Ågren UM, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care 2011;16:444-57. https://doi.org/10.3109/13625187 .2011.604450.

  14. Gaussem P, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011;105:560-7. https://doi.org/10.1160/TH10-05-0327.

  15. Fruzzetti F. Hemostatic effects of smoking and oral contraceptive use. Am J Obstet Gynecol 1999;180:S369-74.

  16. Schumacher M, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 2007;28:387-439. https:// doi.org/10.1210/er.2006-0050

  17. Schindler AE, et al. Clasification and pharmacology of progestins. Maturitas 2008;61:171-80.

  18. Pomp ER, et al. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-02. https://doi.org/10.1002/ ajh.21059

  19. Huerta C, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007;167:935-943. 10.1001/archinte.167.9.935

  20. Naess IA, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9. https://doi.org/10.1111/j.1538- 7836.2007.02450.x

  21. Heinemann LA, et al. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-36. https://doi.org/10.1016/j. contraception.2006.12.018

  22. Jick H, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.

  23. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre casecontrol study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-82.

  24. Løkkegaard E, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423. 10.1136/bmj.d6423.

  25. Lidegaard O, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. https://doi.org/10.1136/bmj.b2890.

  26. Jick SS, et al. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151. https://doi. org/10.1136/bmj.d2151.

  27. de Bastos M, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014;3(3):CD010813. https://doi.org/10.1002/14651858. CD010813.pub2.

  28. van Hylckama Vlieg A, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921. https://doi.org/10.1136/bmj.b2921.

  29. Weill A, et al. Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 2016;353:i2002. https://doi.org/10.1136/bmj.i2002

  30. Mantha S, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012;345:e4944. https://doi. org/10.1136/bmj.e4944

  31. Lidegaard Ø, et al. Venous thrombosis in users of nonoral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012;344:e2990. https://doi.org/10.1136/ bmj.e2990

  32. Arowojolu AO, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2007;(3):CD004425. https://doi.org/10.1002/14651858. CD004425.pub3

  33. Gallo MF, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2008;(4):CD003987. https://doi.org/10.1002/14651858.CD003987.pub3.

  34. Lopez LM, et al. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009;(2):CD006586. https://doi.org/10.1002/14651858. CD006586.pub3.

  35. Sitruk-Ware R. Pharmacologycal profile of progestins. Maturitas 2008;61:151-157.




2020     |     www.medigraphic.com